Glucox Biotech has forged a strategic partnership with the esteemed Karolinska Institutet in Sweden. Together, we are delving deep into the intricacies of NOX4 (NOX2) inhibitors. Our primary focus is understanding their therapeutic potential and how they can revolutionize treatments for kidney disease. 

Specifically, our combined expertise targets individuals prone to acute kidney injury. By bridging the gap between biotech innovation and rigorous academic research, we aim to mitigate and ultimately prevent the onset of such injuries and their associated complications.

Glucox Biotech proudly collaborates with IRIS Pharma, a global frontrunner in preclinical and clinical ophthalmology research services. As we venture into animal studies focusing on safety, pharmacokinetics, and efficacy, IRIS Pharma’s unparalleled expertise proves invaluable. With a 34-year track record, they’ve aided in the launch of over 70 ocular drugs and medical devices.

As a leading Contract Research Organization (CRO) dedicated to ophthalmology, their prowess spans from in vivo ocular efficacy studies to clinical trials. Together, our partnership embodies a synthesis of innovation and proven experience, ensuring advancements in ophthalmic care.